H.C. Wainwright’s $15 target on KRRO

KRRO Korro Bio Inc

$9.79 → $15 (+53%) by Oct 2027

Buy · reiterates · said Oct 6, 2026 · 12-month default horizon

Open: judged on the close on Oct 6, 2027

The article this target came from

H.C. Wainwright reiterates Korro Bio stock rating on trial dosing

Investing.com · Oct 6, 2026

H.C. Wainwright reiterated a Buy rating and $15.00 price target on Korro Bio Inc. following the company's announcement that it has dosed the first cohort of participants in its Phase 1/2 clinical trial for KRRO-121.

H.C. Wainwright’s track record → Korro Bio Inc →

A fact about what H.C. Wainwright published, as reported by Investing.com, not a recommendation from Dalsna Finance; H.C. Wainwright is not affiliated with this site.

Full methodology: how targets are collected, scored, ranked and corrected, what each field means, and how to cite the data.